DES de 2° vs 3° generación en bifurcaciones: nada nuevo bajo el sol

EuroPCR 2018 | 2nd and 3rd-Generation DES for Bifurcation Lesions: Nothing New Under the Sun

This study aimed to assess the outcome of Culotte stenting with newer-generation drug-eluting stents (DES) in Medina 1, 1, 1 bifurcation lesions. The 2nd-generation device used was permanent-polymer everolimus-eluting stent Xience, a device for which there is comparatively plenty of evidence available. Alternatively, the 3rd-generation stent used was thin-strut abluminal bioresorbable-polymer everolimus-eluting stent SYNERGY. Patients with<a href="https://solaci.org/en/2018/05/31/europcr-2018-2nd-and-3rd-generation-des-for-bifurcation-lesions-nothing-new-under-the-sun/" title="Read more" >...</a>

EuroPCR 2018 | SYNTAX II: resultados a 2 años de la mejor angioplastia vs cirugía en múltiples vasos

EuroPCR 2018 | SYNTAX II: Results at 2 Years for Best Angioplasty vs. Surgery in Multivessel Disease

Since the publication of the original SYNTAX trial, there have been great technical advancements that have influenced the results of angioplasty: New tools for risk stratification using the SYNTAX II score which integrate clinical and anatomical variables to the team’s decision-making process. Functional revascularization (hybrid use of fractional flow reserve or instantaneous wave-free ratio). Optimization of<a href="https://solaci.org/en/2018/05/31/europcr-2018-syntax-ii-results-at-2-years-for-best-angioplasty-vs-surgery-in-multivessel-disease/" title="Read more" >...</a>

EuroPCR 2018 | DESSOLV III: polímero bioabsorbible vs durable a 2 años

EuroPCR 2018 | DESSOLV III: Bioabsorbable vs. Durable Polymer at 2 Years

Most drug-eluting stents are coated by a polymer that is used to contain the antiproliferative drug. Once the drug is released, the polymer remains in place and its presence has been associated with inflammation, restenosis, and neoatherosclerosis. The MiStent device features a polymer that becomes bioabsorbable once the drug has been released, which could, theoretically,<a href="https://solaci.org/en/2018/05/31/europcr-2018-dessolv-iii-bioabsorbable-vs-durable-polymer-at-2-years/" title="Read more" >...</a>

EuroPCR 2018 | LEADERS FREE: angioplastias complejas en pacientes con alto riesgo de sangrado

EuroPCR 2018 | LEADERS FREE: Complex Angioplasty in Patients with High Risk for Bleeding

The LEADERS FREE study showed that a biolimus A9-coated polymer-free stent was superior to a conventional stent in terms of safety and efficacy in patients who received dual antiplatelet therapy for only a month due to their high risk for bleeding. In this substudy, researchers analyzed 667 patients enrolled in the original LEADERS FREE trial who met certain requirements<a href="https://solaci.org/en/2018/05/31/europcr-2018-leaders-free-complex-angioplasty-in-patients-with-high-risk-for-bleeding/" title="Read more" >...</a>

Registro Sueco con stent SYNERGY: por primera vez stent probado en angioplastia primaria

EuroPCR 2018 | Swedish Registry on the SYNERGY DES: tested in primary PCI for the first time

The study included 36292 consecutive patients undergoing acute myocardial infarction receiving PCI with the new generation stent SYNERGY (thin struts, bioresorbable polymer and everolimus eluting); 39.7% presented ST elevation MI. Kaplan-Meier curves at 2 years of patients receiving the SYNERGY vs patients receiving other drug eluting stents resulted very similar for thrombosis (0,69% vs 0,81%,<a href="https://solaci.org/en/2018/05/31/europcr-2018-swedish-registry-on-the-synergy-des-tested-in-primary-pci-for-the-first-time/" title="Read more" >...</a>

BIO-RESORT: polímeros vs polímeros bioabsorbibles ¿Llegamos a una meseta con los DES?

EuroPCR 2018 | BIO-RESORT: Polymer vs. Bioresorbable Polymer; Have We Reached a Plateau with DES?

This study randomized 3514 patients to a thin-strut biodegradable polymer everolimus-eluting stent (SYNERGY) vs. a sirolimus-eluting stent (ORSIRO) vs. a durable polymer zotarolimus-eluting stent (RESOLUTE INTEGRITY). The combined endpoint, the rate of target vessel failure, was similar for all three devices (8.3% for the zotarolimos-eluting stent, 6.8% for the everolimus-eluting stent, and 6.6% for the sirolimus-eluting<a href="https://solaci.org/en/2018/05/29/europcr-2018-bio-resort-polymer-vs-bioresorbable-polymer-have-we-reached-a-plateau-with-des/" title="Read more" >...</a>

Registro SCAAR a 10 años: el FFR mejora la toma de decisiones a muy largo plazo

EuroPCR 2018 | SCAAR Registry at 10 years: FFR improves decision making in the long term

The SCAAR registry aimed at showing the differences in mortality at very long term when using functional assessment of coronary lesions (with FFR or iFR) in patients with chronic stable angina. The study compared 3460 patients assessed with FFR/iFR against 21221 patients undergoing PCI based on angiography, between January 2005 and March 2015. As<a href="https://solaci.org/en/2018/05/24/europcr-2018-scaar-registry-at-10-years-ffr-improves-decision-making-in-the-long-term/" title="Read more" >...</a>

Doble antiagregación: menos es más en añosos.

Dual Antiplatelet Therapy: Less Is More for Elderly Patients

A recent meta-analysis that will be published soon in JACC Intv offers evidence of benefit derived from short-term dual antiplatelet therapy for elderly patients. This is a patient group that has always been excluded from the major trials, while remaining one of the most challenging subgroups in which to balance bleeding and ischemic risks. The<a href="https://solaci.org/en/2018/03/27/dual-antiplatelet-therapy-less-is-more-for-elderly-patients/" title="Read more" >...</a>

La cirugía parece superior a la angioplastia en pacientes jóvenes

Surgery Seems Superior to Angioplasty in Young Patients

Long-term follow-up of patients under 50 with multivessel coronary artery disease suggests surgery outcomes are significantly better than angioplasty outcomes. This study, presented at the Society of Thoracic Surgeons’ (STS) Annual Meeting, concludes that surgery should continue as plan A when it comes to young patients with three-vessel disease. Surgeons complain that many patients never actually<a href="https://solaci.org/en/2018/03/22/surgery-seems-superior-to-angioplasty-in-young-patients/" title="Read more" >...</a>

Silent Diabetes Is the New Stealthy Enemy

One in three “nondiabetic” patients who undergo angioplasty with current drug-eluting stents have an altered glucose metabolism, which is associated with a 4-fold higher risk of events, according to a study that will be published soon in JACC Intv. One in three patients is definitely one patient too many, and four times higher is definitely<a href="https://solaci.org/en/2018/03/20/silent-diabetes-is-the-new-stealthy-enemy/" title="Read more" >...</a>